Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic's Revenues Tumble; Firm Continues to Mull Genomics Arm

NEW YORK (GenomeWeb News) — Gene Logic said today its first-quarter revenues fell 63 percent as R&D spending remained flat and net losses narrowed 17 percent.
 
Total receipts for the three months ended March 31 fell to $3.3 million from $8.7 million year over year.
 
All of the company’s revenue came from its genomics services business. Gene Logic reiterated that it has hired outside advisors to “assist in considering strategic alternatives” for its genomics business.
 
R&D was flat for the first quarter at $2.4 million.
 
The company said net losses decreased to $10.1 million from $11.8 million in the year-ago period.
 
As of March 31, Gene Logic had $27.4 million in combined cash and cash equivalents, and $15.7 million in marketable securities.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.